SGPL1 and myalgic encephalomeyelitis/chronic fatigue syndrome: Therefore, with the interest in exploring new therapeutics that target sphingolipid metabolism for ME/CFS, there is a demonstrated need to develop and evaluate new SPL inhibitors with proven efficacy in ameliorating fatigue development and combating neuroinflammation, which requires future research attention.